1842. Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of Clostridium difficile infection
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD

Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of Clostridium difficile infection

S Mitra, C Chilton, J Freeman, M Taylor, P Quirke, H Wood, RJ Vickers, MH Wilcox

Background: Clostridium difficile infection (CDI) is a major cause of nosocomial diarrhoea associated with antimicrobial-mediated dysbiosis. Dysbiosis may be perpetuated by antibiotic (AB) CDI therapy, leading to recurrent CDI. Ridinilazole (RIDI) has very narrow activity against certain clostridia. We measured faecal microbiomes of Phase 2 subjects randomised to 10 days of RIDI or fidaxomicin (FDX) for CDI.

Methods: Faecal samples (27 patients) were obtained at study entry (DM1-D1), Day 2 (D2-D3), Day 5 (D4-5), Day 7 (D5-7), Day 10 (D9-10), Day 12 (D11-14), Day 25 (D15-25), D30 (D25-30), Day 40 (D40+) and grouped according to blinded treatment (Drug A or B). DNA was extracted using the QIAamp DNA Stool Mini Kit (Qiagen), and 16S V4 PCR products sequenced on an Illumina MiSeq®. Samples were analysed as a full dataset (n=154) and as subgroups: no concomitant (con)AB or prior CDI AB (n=67); no conAB but prior CDI AB (n=44); total no conAB (n=111). Data were quality controlled and annotated (QIIME, Usearch, Greengenes, PyNAST, RDP). OTU files were imported in MEGAN for further analyses.  

Results: Comparable sustained clinical response rates to 30 days post end of therapy were seen with RIDI (50%) compared to FDX (46.2%); estimated treatment difference 2.9% (95% CI -30.8, 36.7). Following unblinding (drug A=RIDI, drug B=FDX), Simpsons diversity indices showed marked microbiome differences at family level for RIDI vs FDX subjects in multiple analyses. This was most marked for no conAB or prior CD AB and total no conAB subjects, in whom RIDI microbiome diversity was markedly greater (approaching significance) during CDI treatment and significantly greater at D11-D14 and D4-5, D6-8, respectively (p<0.05) (Figure).  In particular, Bifidobacteriaceae and Ruminococcaceae populations, previously linked to colonisation resistance, were more stable during RIDI treatment.

Conclusion: RIDI preserved gut microbiome diversity to a greater extent than FDX during CDI treatment. Differences were most marked for, but not restricted to, patients receiving no conAB. Microbiome sparing by RIDI is consistent with low CDI recurrence rates.

Suparna Mitra, PhD1, Caroline Chilton, PhD1, Jane Freeman, PhD1,2, Henry Wood, PhD3, Phil Quirke, BM, PhD3, Morag Taylor, M.Sc3, Richard Vickers, PhD4 and Mark Wilcox, MD1,5, (1)Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom, (2)Leeds Teaching Hospitals, Leeds, United Kingdom, (3)Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, (4)Summit Therapeutics plc, Oxford, United Kingdom, (5)Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom

Disclosures:

S. Mitra, None

C. Chilton, Astellas: Investigator and Speaker's Bureau , Research grant and Speaker honorarium
Da Volterra: Investigator , Research grant
Paratek pharmaceuticals: Investigator , Research grant
Actavis: Investigator , Research grant

J. Freeman, Astellas: Investigator , Research grant
Morphochem: Investigator and Research Contractor , Research support
Melinta: Research Contractor , Research support

H. Wood, None

P. Quirke, None

M. Taylor, None

R. Vickers, Summit plc: Employee , share options

M. Wilcox, Merck & Co., Inc.: Consultant , Consulting fee
Cubist: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Alere, Actelion Pharma, Astellas, Optimer, Sanofi Pasteur, Summit Pharma, bioMerieux, Da Volterra, Qiagen, Cerexa, Abbott, AstraZeneca, Pfizer, Durata Therapeutics, Seres Therapeutics, Valneva, Nabriva Therapeutics, Roche, The Medicines Company, Basilea P: Consultant , Consulting fee
Alere, Actelion Pharmaceuticals, Pharmaceuticals, Astellas, Optimer Pharmaceuticals, Sanofi Pasteur, Summit Pharmaceuticals, bioMerieux, Da Volterra, Qiagen, Cerexa, and Abbott: Grant Investigator , Grant recipient

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.